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This study compared immediate (overnight) and progressive switching to oxcarbazepine monotherapy in patients with partial
seizures unsatisfactorily treated with carbamazepine monotherapy. Patients were randomised to either an overnight (n = 140) or a
progressive switch (n = 146) from carbamazepine to oxcarbazepine monotherapy at a dose ratio of 1:1.5. The difference between
the two switch groups in the mean monthly seizure frequency supported the equivalence of overnight and progressive switching
(difference of 0.02 excluding outliers; 95% confidence interval (CI) −0.74, 0.78). Following the switch from carbamazepine
to oxcarbazepine, there was a reduction in median monthly seizure frequency in both the overnight group (from 1.5 to 0;
P = 0.0005) and the progressive group (from 1.0 to 0.4; P = 0.003). The proportion of seizure-free patients increased from 38
to 51% (P = 0.002) and 39 to 49% (P = −0.01) in the overnight and progressive groups, respectively. In addition, the proportion
of patients experiencing no clinically significant adverse events did not differ between the two switch methods (difference of
2.5; 95% CI −4.1, 9.0).
For patients who are unsatisfactorily treated with carbamazepine monotherapy, overnight switch to oxcarbazepine monotherapy
is as effective and well tolerated as a progressive switch, therefore allowing simple and flexible individualised treatment.
Switching to oxcarbazepine monotherapy appears to be beneficial for patients who are unsatisfactorily treated with carbamazepine
monotherapy, independently of the switch method used.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
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INTRODUCTION
The majority of the estimated 50 million people af-
fected by epilepsy worldwide have a good prognosis,
but around 30% do not achieve adequate control
of their seizures1,2. The main goal of treatment for
epilepsy is to achieve optimum seizure control and
tolerability, preferably with a single antiepileptic
drug (AED). Monotherapy is suitable for most pa-
tients: recent findings suggest that 47% of patients
who have not previously received AED treatment
become seizure free on their first AED, and a fur-
ther 13% become seizure free on monotherapy with
a second or third AED3. When monotherapy fails
and patients experience an unacceptable number
of seizures or side effects that interfere with their
normal daily activities, ‘switching’ AED treatment
is the next most likely option in current clinical
practice.
Physicians generally choose to switch patients
progressively from one AED to another over sev-
eral weeks. Besides the existing differences between
carbamazepine and oxcarbazepine (especially carba-
mazepine oxidative metabolism generating an epoxide
metabolite, vs. conjugation for oxcarbazepine), the
analogy of chemical structures and sodium-channel
blockade mechanisms suggest that they may be
switched on an immediate basis (overnight). In ad-
dition, clinical experience supports the possibility of
overnight switching from carbamazepine to oxcar-
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bazepine, but there is no consensus on the risk for
increased side effects or suitability for patients intol-
erant or refractory to carbamazepine of such rapid
conversion method4–7.
Oxcarbazepine is a new-generation AED indicated
for use as monotherapy or combination therapy in
adults and children (in the US as adjunctive therapy
only in children) with partial seizures, including the
subtypes of simple and complex, and secondarily
generalised tonic-clonic seizures (in some coun-
tries, it is also indicated for primary generalised
tonic-clonic seizures). Conversion to oxcarbazepine
monotherapy, both from carbamazepine and other
AEDs, has been shown to be effective in improving
seizure control and tolerability in controlled clini-
cal trials and from extensive clinical experience8–13.
However, there are few published reports directly
comparing overnight with progressive switch14,15.
We conducted the first randomised, open-label study
to compare overnight and progressive switch to ox-
carbazepine monotherapy in patients with partial
seizures unsatisfactorily treated with carbamazepine
monotherapy.
METHODS
Patients
Male or female outpatients aged ≥14 years with a
diagnosis of partial seizures (including the subtypes
of simple, complex and partial seizures evolving to
secondarily generalised seizures) were recruited into
the study. All patients were unsatisfactorily treated
with therapeutic levels of carbamazepine monotherapy
and required a switch for one or more of the following
reasons:
• inability to achieve satisfactory seizure control due
to dose-limiting side effects experienced with car-
bamazepine;
• inability to adequately tolerate carbamazepine
monotherapy even in the presence of acceptable
seizure control;
• patients who, despite achieving adequate seizure
control, were prone to recurrent clinical conditions
requiring treatment with drugs known to interact
with carbamazepine.
Patients were not eligible if they experienced pri-
mary generalised or pseudo-seizures, had a history
of status epilepticus in the 6 months prior to screen-
ing, or experienced seizures only occurring in clus-
tered patterns (defined as serial seizures occurring
within a 30-min period). Patients were also not per-
mitted to enter the study if they had progressive
lesions as shown by magnetic resonance imaging
or computed tomography. Other grounds for exclu-
sion included evidence of any medically relevant
disorder likely to significantly impact the study out-
come, serum sodium levels outside the normal range
of local laboratories (on average 135–145 mmol/l),
changes in laboratory values not considered to be
directly related to carbamazepine therapy, preg-
nancy or lactation, a history of psychiatric distur-
bance within the 6 months prior to randomisation
that required treatment (including suicide attempts
and substance abuse), and known hypersensitivity
to oxcarbazepine (patients with a history of hyper-
sensitivity to carbamazepine were however eligi-
ble).
Tricyclic antidepressants and selective serotonin re-
uptake inhibitors were permitted in low doses during
the study.
Study design
This was a multicentre, randomised, open-label,
parallel-group study designed to assess the thera-
peutic equivalence of immediate (overnight) and
progressive switching from carbamazepine to ox-
carbazepine. The study consisted of two phases:
screening and open-label treatment. Patients entered
the screening phase of up to 2 months to collect
data on seizure type and frequency unless these
data could be obtained retrospectively from a pa-
tient diary or other document considered reliable by
their physician. At the end of the screening phase,
patients were randomised (1:1) to one of the two
switch methods. The 2-month, open-label treatment
phase was divided into two periods: switch and
maintenance (Fig. 1) and comprised three scheduled
clinic visits: at randomisation (Visit 1), the second
day after end of switch (Visit 2), and the end of
the 2-month, open-label treatment phase (Visit 3).
At Visit 1 (randomisation), inclusion and exclusion
criteria were checked, a complete physical and neu-
rological examination was carried out, and epilepsy
history and baseline seizure frequency were gath-
ered. Laboratory assessments were carried out at
Visits 1 and 3. Seizure frequency, adverse events
and treatment satisfaction were assessed at Visits 2
and 3.
Patients remained as outpatients throughout the
open-label treatment phase and were advised to call
their physician if any problems arose. Seizures were
recorded continuously during the study using patient
diaries and were classified according to the Interna-
tional Classification of Epileptic Seizures16 and the
International Classification of Epilepsies and Epilepsy
Syndromes17 from the International League Against
Epilepsy.
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Fig. 1: Study design.
Treatment
Switching period
Patients assigned to an overnight switch had their
carbamazepine treatment immediately replaced with
oxcarbazepine at a daily dose ratio of 1:1.5 (carba-
mazepine: oxcarbazepine). Patients assigned to pro-
gressive switching had their carbamazepine treatment
replaced with oxcarbazepine (Tolep®, non-coated
tablet) at the same daily dose ratio, but on a slower
basis. In both cases, replacement was done on a ‘tablet
by tablet’ basis; for example, a 200 mg carbamazepine
tablet was to be replaced by a 300 mg oxcarbazepine
tablet, regardless of whether their regimen was b.i.d.
or t.i.d. No dose adjustments were allowed during
the switching period. Patients unable to complete the
switch were withdrawn from the study.
Immediate (overnight) switching could be com-
pleted on the day after randomisation. For example,
a patient receiving 400 mg b.i.d. carbamazepine on
Day 0 (randomisation) could be instructed to take
600 mg b.i.d. oxcarbazepine on Day 1. However, if
the investigator considered that patient tolerability
could be optimised by a night of sleep between the
first and second oxcarbazepine dose, the first dose
could be given in the evening of Day 0 instead of
the scheduled carbamazepine dose, and the second
oxcarbazepine dose could be given on the morning of
Day 1. Therefore, Day 1 was the first day on which
any patient received only oxcarbazepine.
For progressive switching, carbamazepine was re-
placed by oxcarbazepine every second day until total
substitution was achieved, but daily dose increments
of >300 mg oxcarbazepine were not allowed. For ex-
ample, carbamazepine 400 mg tablets could be halved
so that each 200 mg part could be substituted with a
300 mg oxcarbazepine tablet every second day. Sub-
stitution was also permitted every third day in cases
where slower titration was indicated. Patients were
therefore receiving carbamazepine and oxcarbazepine
concomitantly until the switch was completed. The to-
tal duration of progressive switches was variable, de-
pending on the total daily dose of carbamazepine the
patient was initially receiving.
Maintenance period
Oxcarbazepine dose adjustments were allowed (as
warranted by the investigator) at any time during the
maintenance period, if clinically indicated.
Assessments
Efficacy variables
The primary efficacy endpoint was the individual aver-
age number of seizures per month from randomisation
until study end. Secondary efficacy endpoints were the
‘between-group’ and ‘within-group’ differences in the
mean of the average monthly seizure frequency before
and after the switch (2 months’ screening, 2 months’
treatment).
Safety variables
The primary tolerability endpoint was the proportion
of patients who did not experience any clinically sig-
nificant adverse events during the switch period, which
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was defined as starting on the day of the first oxcar-
bazepine dose and ending one day after the last oxcar-
bazepine monotherapy dose was administered. Clini-
cally significant adverse events were defined as events
that were considered moderate or severe by the investi-
gator, required specific medical intervention, or led to
modification or interruption of AED therapy. The sec-
ondary tolerability endpoint was the ‘between-group’
difference in the proportion of patients with no clin-
ically significant adverse events over the 2-month,
open-label treatment phase as assessed at Visit 3.
Safety was assessed on the basis of adverse events,
physical and neurological examinations, vital signs
and laboratory tests. At the end of the switch period
and at study completion, patients and physicians also
performed a Global Assessment of Treatment Satis-
faction by rating their satisfaction with treatment on a
4-point scale as ‘poor’, ‘fair’, ‘good’ or ‘very good’.
Statistical analysis
The average monthly seizure frequency was calcu-
lated by dividing the number of observed seizures for
a given patient by the length of the open-label treat-
ment phase in days and multiplying by 30.5. Equiva-
lence between the two switch methods was established
by calculating the two-sided 95% confidence intervals
(CI) of the ‘between-group’ difference of the means
of the average number of seizures per month during
the open-label treatment phase.
A sample size of 140 patients per group (280 to-
tal) was initially calculated to give the study 80%
power to demonstrate equivalence assuming a max-
imum non-clinically relevant ‘between-group’ differ-
ence in the mean number of seizures per month of 1.0
with a standard deviation of three seizures per month,
and that the observed difference between the groups
would not exceed 0.3 seizures per month. In addition,
a secondary analysis compared the seizure frequency
within each treatment group before and after switch-
ing, using the Wilcoxon signed-rank test and between
groups using the Mann–Whitney U-test.
Non-inferiority of tolerability after overnight
switching was calculated by comparing the proportion
of patients who did not experience clinically signifi-
cant adverse events between groups. The maximum
non-clinically relevant ‘between-group’ difference in
the proportion of patients who did not experience
clinically significant adverse events during the switch
was set to 10%. It was hypothesised that the pro-
portion of patients falling into this category in the
progressive-switch group would not be <87% and that
the observed difference between groups would not be
>3.4%. A total of 140 patients were necessary to give
the study 80% power and demonstrate non-inferiority
of tolerability for overnight versus progressive switch-
ing (for the one-sided 95% CI to extend 6.6% from
the observed ‘between-group’ difference).
Analyses were carried out on all patients switched
to oxcarbazepine and receiving at least one dose, in-
cluding those who did not complete the maintenance
phase (the evaluable patient population).
RESULTS
Patient characteristics
A total of 288 patients at 41 centres in Italy were
randomised to undergo a switch from carbamazepine
to oxcarbazepine monotherapy. Two patients did not
receive study medication. Overall, 286 patients were
evaluable: 140 and 146 patients in the overnight- and
progressive-switch groups, respectively. The baseline
characteristics of all randomised patients are shown in
Table 1.
The baseline characteristics of the two switch
groups were comparable, including seizure frequency
and age. The proportion of males to females (57.1%
vs. 42.9%, respectively) in the overnight-switch
group was reversed in the progressive group (41.1%
vs. 58.9%, respectively). The majority of patients in
both switch groups (65.0%) required a switch from
carbamazepine due to inadequate tolerability.
Overall, 93.4% of the patients completed the study:
94.3% (132/140) in the overnight- switch group and
92.5% (135/146) in the progressive-switch group. A
total of 19 patients discontinued prematurely (3 dur-
ing switch, 16 during maintenance): 10 due to adverse
events, 5 due to unsatisfactory therapeutic effect, 2 due
to protocol violations, and 2 patients withdrew con-
sent. Of the 3 patients who discontinued during the
switch, 1 patient in the overnight-switch group was
withdrawn due to an adverse event (diffuse cutaneous
eruption), 1 of the 2 patients in the progressive-switch
group was withdrawn due to adverse events (mem-
ory impairment, vertigo, headache), and the other was
withdrawn due to lack of efficacy. For the 16 patients
who discontinued while on maintenance therapy, irre-
spective of the switch group, the mean (range) dura-
tion of maintenance therapy was 23.4 (1.0–54.0) days,
out of a maximum of 2 months.
Study treatment
Mean (range) switch duration was 1.4 (1.0–3.0) days
in the overnight group and 7.0 (2.0–16.0) days in
the progressive group. Last mean daily doses of car-
bamazepine before switch were 786.4 and 764.4 mg
in the overnight and progressive groups, respectively,
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Table 1: Baseline characteristics.
Characteristic Overnight switch (n = 140) Progressive switch (n = 146)
Mean age (range), years 44.0 (17–82) 42.1 (16–84)
Male:female (%) 57.1:42.9 41.1:58.9
Reason for undergoing switch, n (%)a
Unsatisfactory control 73 (52.1) 70 (47.9)
Inadequate tolerability 89 (63.6) 98 (67.1)
Need of treatment with interacting drugs 5 (3.6) 4 (2.7)
Mean number of seizures per month 3.1 2.6
Mean final dose of carbamazepine before
starting switch, mg per day (SD)
786.4 (286.9) 764.4 (294.0)
Type of carbamazepine received, n (%)b
Tegretol® 55 (39.6) 60 (41.1)
Tegretol CR® 84 (60.0) 86 (58.9)
Patients receiving non-AED concomitant
medications, n (%)
43 (30.7) 44 (30.1)
Medications received by ≥3% patients (n)
Renin-angiotensin system inhibitorsc 9 9
Antithrombotics 11 7
Anti-inflammatories 5 5
Calcium-channel blockersb 6 4
Antacids 6 3
Hormonal agentsb 3 6
SD, standard deviation; AED, antiepileptic drug.
a Patients could have more than one reason for switching.
b Information unavailable for one patient.
c Includes medications that can potentially interact with oxcarbazepine.
and daily doses ranged from 200 to 1600 mg. Follow-
ing the switch to oxcarbazepine, the mean duration of
maintenance treatment was 60.9 and 58.4 days for the
overnight and progressive groups, respectively. Most
patients (80.8%) switching progressively had oxcar-
bazepine substituted for carbamazepine every 2 days.
At study end, both groups of patients were receiv-
ing similar mean doses of oxcarbazepine (1186.0 and
1138.5 mg per day for the overnight and progressive
groups, respectively), and the mean dose ratios of
carbamazepine:oxcarbazepine were 1:1.56 (overnight
group) and 1:1.55 (progressive group).
Efficacy
The difference between groups in the primary efficacy
endpoint (the average monthly seizure frequency dur-
ing open-label treatment) supported the equivalence
of overnight and progressive switching, as shown in
Table 2. As the individual values for seizure frequency
were not normally distributed (i.e. were asymmetric;
Fig. 2), median values were used to compare the effi-
cacy of overnight and progressive switch methods in
the first instance. When 8 outliers (4 patients in each
group with >25 monthly seizures at any point) were
excluded from the analysis, mean values also sup-
ported the equivalence of the two switching methods
(Table 2).
The secondary analyses on the overall comparisons
of before versus after switch clearly show that patients
benefited significantly from both types of switching
(Table 2 and Fig. 2). There was an overall improve-
ment in monthly seizure frequency after switching
(difference of the means from baseline = −0.94,
95% CI −2.18, 0.30). Following the switch from car-
bamazepine to oxcarbazepine, there was a reduction
in the median monthly seizure frequency in both the
overnight group (from 1.5 to 0, P = 0.0005) and
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Fig. 2: Individual variation in seizure frequency in patients
who completed overnight or progressive switches to
oxcarbazepine monotherapy.
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Table 2: Comparison of average monthly seizure frequencies.
Overnight switch (n = 140) Progressive switch (n = 146)
Before switch
Mean number of monthly seizures 3.1 2.6
Median number of monthly seizures 1.5 1.0
Range 0–32 0–30
Seizure-free patients (%) 37.9 39.0
After switch
Mean number of monthly seizures 2.3 2.7
Median number of monthly seizures 0 0.4
Range 0–33 0–59
Seizure-free patients (%) 50.7 49.3
Wilcoxon signed rank test for before versus
after in the number of monthly seizures
0.0005 0.003
McNemar’s test for before versus after in
the seizure-free percentages
0.002 0.01
Between-group difference in means (95% CI) −0.40 (−1.79, 0.98)
Excluding outliersa 0.02 (−0.74, 0.78)
Difference of the medians (95% CI) 0.0 (0.0, 0.0)
Difference in the mean change from baseline (95% CI) −0.94 (−2.18, 0.30)
Note. All P-values are two-sided. Because the mean values are heavily influenced by a few very large values, the non-parametric
Wilcoxon signed rank test is used to test the within-group difference, as specified in the protocol.
To demonstrate equivalence, 95% CI values should not exceed 1.0, based on the maximum non-clinically relevant difference in the
monthly number of seizures being set to 1.0.
a Outliers were patients with >25 monthly seizures either at baseline or after randomisation (four patients in each group). There were
four outliers in each group: three patients had >25 monthly seizures at baseline; four patients had >25 monthly seizures after
randomisation; one patient had >25 monthly seizures both at baseline and after randomisation.
the progressive group (from 1.0 to 0.4, P = 0.003;
Wilcoxon signed-rank test).
The benefit of switching is also shown with the
proportion of seizure-free patients on oxcarbazepine
monotherapy. During screening, 110 patients out of
286 (38.5%) had no seizures (103/187 switching for
lack of tolerability, 7/9 for need of interacting drugs).
None of the 143 patients switching for unsatisfactory
seizure control were previously seizure-free. The num-
ber of seizure-free patients increased from 53 (37.9%)
to 71 (50.7%) in the overnight group after switching
(P = 0.002) and from 57 (39.0%) to 72 (49.3%) in
the progressive group (P = 0.010; McNemar’s test),
respectively. Again, the overnight switch seems to of-
fer a little better seizure control.
Furthermore, there was no significant difference be-
tween male and female patients in median monthly
seizure frequency (0.21 vs. 0.23, P = 0.554). Thus,
the apparent imbalance in the gender distribution of
the two switching types should not be a concern in the
efficacy comparisons.
Of the 143 patients switching due to unsatisfactory
seizure control on carbamazepine, 46.1% showed a de-
crease in monthly seizure frequency of ≥50%. There
was a potential trend favouring overnight switching
for these patients, with median monthly seizure re-
ductions of 1.7 (from 3.3 at baseline) in the overnight
group versus 1.3 (from 3.9 at baseline) in the pro-
gressive group (P < 0.05; Fig. 3). In addition, 50.7%
of patients who switched overnight experienced a de-
crease of ≥50% in monthly seizure frequency, com-
pared with 41.4% of patients who switched progres-
sively. Patients switching due to poor tolerability on
carbamazepine also experienced significant improve-
ments in seizure frequency after switching to oxcar-
bazepine: P = 0.01 and P = 0.05 in the overnight
and progressive groups, respectively.
Safety and tolerability
A total of 90.0 and 92.5% of patients experienced
no clinically significant adverse events during switch-
ing in the overnight and progressive groups, respec-
tively. The 95% CI of the ‘between-group’ difference
did not exceed 10% (difference of 2.5; 95% CI −4.1,
9.0) and therefore demonstrated the non-inferiority of
overnight- and progressive-switch methods.
Where switches were carried out due to poor tolera-
bility with carbamazepine (n = 187), 88.8 and 90.8%
of patients were judged not to have experienced clin-
ically significant adverse events in the overnight and
progressive groups, respectively (difference of 2.1;
95% CI −6.7, 10.8). In addition, for the treatment
phase as a whole (switch and maintenance), 80.7 and
82.9% of physicians rated their patients not to have
experienced such events with oxcarbazepine for the
overnight and progressive groups, respectively (dif-
ference of 2.2; 95% CI −6.8, 11.1). Although the
study was not powered to demonstrate non-inferiority
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Fig. 3: Seizure frequency before and after starting oxcarbazepine monotherapy in patients switching due to lack of seizure
control with carbamazepine.
in these secondary analyses, 95% CI values were close
to the predetermined 10% limit.
Overall, 14 patients (10.0%) who switched overnight
and 11 patients (7.5%) who switched progressively
were judged to have experienced clinically signif-
icant adverse events. Of these patients, 10/14 and
9/11, respectively, had experienced poor tolerability
with carbamazepine. In the subpopulation switch-
ing from carbamazepine due to poor tolerability,
carbamazepine-related adverse events were com-
pletely or partially resolved in nearly 90% of patients
(Fig. 4). There was no significant difference between
the proportions of male and female patients reported to
have experienced clinically significant adverse events
at the end of switch (8.6% vs. 8.9%, P = 0.921).
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Fig. 4: Resolution of carbamazepine-related adverse events in patients switching to oxcarbazepine monotherapy due to poor
tolerability on carbamazepine.
For the study as a whole, adverse events were in line
with the known tolerability and safety profiles of ox-
carbazepine (Table 3). During the switch period, the
most frequently reported treatment-emergent adverse
events judged as clinically significant (>1 patient in
either group) were nausea, headache, vertigo, somno-
lence and paresthesia (Table 3). Overall, 10 patients
(7.1%) who switched overnight and 9 patients (6.2%)
who switched progressively discontinued the study
due to an adverse event. Four overnight-switch pa-
tients and two progressive-switch patients experienced
serious adverse events during the open-label treatment
phase. In the overnight-switch group, these serious
events (all n = 1) were allergic dermatitis (patient
discontinued), fever (resolved after 8 days), headache
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Table 3: Adverse events.
Patients, n (%)
Overnight switch
(n = 140)
Progressive switch
(n = 146)
Adverse events considered related
to treatment overall (>1 patient in
either group)
Vertigo 2 (1.4) 3 (2.1)
Nausea 3 (2.1) 1 (0.7)
Somnolence 2 (1.4) 2 (1.4)
Convulsions 2 (1.4) 1 (0.7)
Headache 1 (0.7) 2 (1.4)
Asthenia 0 (0.0) 2 (1.4)
Diplopia 2 (1.4) 0 (0.0)
Paresthesia 0 (0.0) 2 (1.4)
Adverse events judged to be
clinically significant during switch
(≥1 patient in either group)
Nausea 3 (2.1) 1 (0.7)
Headache 2 (1.4) 2 (1.4)
Vertigo 2 (1.4) 2 (1.4)
Somnolence 1 (0.7) 2 (1.4)
Paresthesia 0 (0.0) 2 (1.4)
(with aggravation of seizures) and hyponatraemia (re-
solved after 10 days, patient discontinued). This was
the only case of hyponatraemia and occurred in a pa-
tient undergoing an overnight switch; serum sodium
levels for this patient were 135 mmol/l at baseline and
136 mmol/l at study end. In the progressive-switch
group, the serious adverse events were aggravation of
seizures (n = 1) and partial seizure associated with
fracture of the arm (n = 1, patient discontinued treat-
ment).
There were no important changes in the mean values
of haematological and biochemical laboratory tests.
A small number of abnormal laboratory values (in-
creases) were recorded during treatment with oxcar-
bazepine (blood urea nitrogen, aspartate aminotrans-
ferase, gamma-glutamyl transpeptidase, alkaline phos-
phatase, calcium and potassium). There were no sig-
nificant differences in the pattern or extent of labora-
tory values between the two switch methods.
Overall treatment satisfaction
At the end of the switch period, 90.7 and 87.0%
of physicians rated overall treatment satisfaction for
overnight and progressive switching to be ‘good’
or ‘very good’, respectively. Furthermore, 88.6 and
85.6% of patients also rated their overall treatment
satisfaction for overnight and progressive switching
to be ‘good’ or ‘very good’, respectively.
DISCUSSION
This study demonstrates the validity and clinical fea-
sibility of two methods of switching (overnight and
progressive) from carbamazepine monotherapy to
oxcarbazepine monotherapy in patients with partial
seizures. To our knowledge, it is the first study to
directly and systematically compare two methods of
switching from carbamazepine to oxcarbazepine. The
difference between groups in the average monthly
number of seizures after the switch confirms that
there is no significant difference in the utility of these
switch methods. This conclusion is supported by
the accumulating evidence coming from all analyses
done on medians and excluding the outliers, which
were done in an attempt to overcome the distribu-
tional problems of the primary variable. The main
relevance of these findings for daily practice is that
oxcarbazepine allows flexibility in tailoring treat-
ment switch strategies at the individual patient level.
Furthermore, overnight switch from carbamazepine
monotherapy to oxcarbazepine monotherapy may be
most appropriate for patients who experience poor
seizure control on carbamazepine, as this subgroup
of patients appeared to benefit more from overnight
switching in our study.
The difference in seizure frequency after switch,
shows the overall benefit of switching to oxcar-
bazepine monotherapy for patients with partial
seizures who are unsatisfactorily treated with car-
bamazepine monotherapy, both in terms of efficacy
and safety. Switching from carbamazepine to oxcar-
bazepine monotherapy was associated with a better
response, as there was a decrease in average monthly
seizure frequency and an increase in the percent-
age of seizure-free patients. Seizure control was
increased both in patients previously uncontrolled
on or intolerant to previous carbamazepine therapy.
Tolerability was improved after switch overall with
improvement or resolution of previous side effects on
carbamazepine in more than 88% of cases.
Guidelines and data-based reviews confirm that
an overnight switch is suitable for patients who
are receiving carbamazepine monotherapy, but are
intolerant of its side effects or experience inade-
quate seizure control5–7,18,19. However, it has been
noted that when patients receive ≥800 mg/day car-
bamazepine, they may experience increased side ef-
fects during rapid switching. Variation in the degree
of carbamazepine autoinduction between patients is
thought to be responsible for this effect and can lead
to widely different serum drug levels from the same
oral dose6. Although daily doses of carbamazepine
ranged from 200 to 1600 mg in the current study,
and some patients taking controlled-release carba-
mazepine received oxcarbazepine concomitantly dur-
ing immediate switch, the high proportion (≥90%) of
patients who did not experience clinically significant
adverse events during the switch period supported the
non-inferiority of overnight switching. There were no
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safety concerns associated with either overnight- or
progressive-switch methods.
Monotherapy studies with active comparators have
demonstrated improved tolerability and equivalent
efficacy of oxcarbazepine compared with carba-
mazepine and phenytoin, and similar tolerability and
efficacy compared with valproate4,20–22. These stud-
ies have established that oxcarbazepine is a valuable
first-choice treatment option for initiating therapy in
newly diagnosed patients with partial seizures. How-
ever, the current study underlines that oxcarbazepine
may also provide effective seizure control and is well
tolerated in patients in which a previous monotherapy
with carbamazepine has failed.
Oxcarbazepine was well tolerated throughout the
open-label treatment phase regardless of the switch
method. Approximately 90% of patients who switched
from carbamazepine due to tolerability problems did
not experience these problems, fully or in part, on
oxcarbazepine monotherapy. Ten patients (7.1%) in
the overnight group and nine patients (6.2%) in the
progressive group experienced adverse events that
led to discontinuation from the study. As expected,
the discontinuation events were mainly those affect-
ing the central nervous system, with the exception
of one case each of hyponatraemia, pruritis and der-
matitis. The proportion of discontinuations compared
favourably with published studies of patients initi-
ating or switching to oxcarbazepine monotherapy,
where 3.5–17.4% of patients discontinued due to
adverse events12,13,20,22,23.
The clinical efficacy and good tolerability observed
during the overnight switches in this study suggest that
future investigations could examine overnight switch-
ing in patients receiving carbamazepine as combina-
tion therapy. Cost-benefit analysis should also be con-
sidered, since overnight switching potentially involves
less monitoring and less cost than more protracted
methods of treatment conversion.
In conclusion, for patients who are unsatisfactorily
treated with carbamazepine monotherapy, overnight
switch to oxcarbazepine monotherapy was as ef-
fective and well tolerated as a progressive switch.
Therefore, switch to oxcarbazepine is easy to perform
with full flexibility in individualising patient care.
Overall, patients benefited from switching to oxcar-
bazepine monotherapy independently of the switch
method used, with respect to either safety, tolerability,
efficacy or to all combined.
Appendix A
The Italian PRIMO Study Group comprised the
following: Aguglia U. (Reggio Calabria), Albano
C. (Genova), Antonini L. (Brescia), Avanzini G.
(Milan), Baruzzi A. (Bologna), Basso P. (Gallarate,
VA), Benna P. (Turin), Canger R. (Milan), Consoli D.
(Vibo Valentia), D’Alessandro P. (Perugia), Daniele O.
(Palermo), Defanti C.A. (Milan), Ferrari G. (Verona),
Garofalo P. (Vicenza), Giallonardo A.T. (Rome),
Giordana M.T. (Orbassano, TO), Liguori G. (Nocera
Inferiore, SA), Marrosu F. (Monserrato, CA), Masè
G. (Trieste), Mazza S. (Rome), Minicucci F. (Milan),
Murri L. (Pisa), Muscas G. (Florence), Musumeci S.
(Troina, EN), Paggi A. (Ancona), Passarella B. (Brin-
disi), Puca F. (Bari), Santamato V. (Carbonara, BA),
Sterzi R. (Como), Striano S. (Naples), Tanganelli
P. (Genova), Tassinari C.A. (Bologna), Tassinari T.
(Pietra Ligure, SV), Tata R. (Naples), Vatti G. (Siena),
Zucca C. (Bosisio Parini, CO).
REFERENCES
1. Brodie, M. J., Shorvon, S. D., Canger, R., Halasz, P., Jo-
hannessen, S., Thompson, P. et al. Commission on European
Affairs: appropriate standards of epilepsy care across Europe:
ILEA. Epilepsia 1997; 38: 1245–1250.
2. ILAE Commission report: the epidemiology of the epilep-
sies: future directions. International League Against Epilepsy.
Epilepsia 1997; 38: 614–618.
3. Kwan, P. and Brodie, M. J. Early identification of refractory
epilepsy. New England Journal of Medicine 2000; 342: 314–
319.
4. Dam, M., Ekberg, R., Loyning, Y., Waltimo, O. and Jakob-
sen, K. A double-blind study comparing oxcarbazepine and
carbamazepine in patients with newly diagnosed, previously
untreated epilepsy. Epilepsy Research 1989; 3: 70–76.
5. Dam, M. Practical aspects of oxcarbazepine treatment. Epilep-
sia 1994; 35 (Suppl. 3): S23–S25.
6. Smith, P. E. M. for the UK Oxcarbazepine Advisory Board.
Clinical recommendations for oxcarbazepine. Seizure 2001;
10: 87–91.
7. Schmidt, D., Arroyo, S., Baulac, M., Dam, M., Dulac, O.,
Friis, M. L. et al. Recommendations on the clinical use of
oxcarbazepine in the treatment of epilepsy: a consensus view.
Acta Neurology Scandinavian 2001; 104: 167–170.
8. Friis, M. L., Kristensen, O., Boas, J. et al. Therapeutic expe-
riences with 947 epileptic outpatients in oxcarbazepine treat-
ment. Acta Neurology Scandinavian 1993; 87: 224–227.
9. Van Parys, J. A. and Meinardi, H. Survey of 260 epilep-
tic patients treated with oxcarbazepine (Trileptal) on a
named-patients basis. Epilepsy Research 1994; 19: 79–85.
10. Sachdeo, R. C., Edwards, K., Hasegawa, H. et al. Safety
and efficacy of oxcarbazepine 1200 mg/day in patients with
recent-onset partial epilepsy. Neurology 1999; 52 (Suppl. 2):
A391.
11. Schachter, S. C., Vazquez, B., Fisher, R. S., Laxer, K. D.,
Montouris, G. D., Combs-Cantrell, D. T. et al. Oxcarbazepine:
double-blind, randomized, placebo-control, monotherapy trial
for partial seizures. Neurology 1999; 52: 732–737.
12. Beydoun, A., Sachdeo, R. C., Rosenfeld, W. E., Krauss, S. L.,
Sessler, N., Mesenbrink, P. et al. Oxcarbazepine monotherapy
for partial-onset seizures. Neurology 2000; 54: 2245–2251.
13. Sachdeo, R., Beydoun, A., Schachter, S., Vazquez, B.,
Schaul, N., Mesenbrink, P. et al. Oxcarbazepine (Trileptal)
as monotherapy in patients with partial seizures. Neurology
2001; 57: 864–871.
14. Rosenfeld, W. E., Lippmann, S. M., Montouris, G. D., Schae-
fer, P. A., Cerone, P. K. and Fisher, L. J. Potential dosing
Immediate (overnight) switching from carbamazepine to oxcarbazepine monotherapy 263
methods for oxcarbazepine. Epilepsia 2000; 41 (Suppl. 7):
228.
15. Homberg, V., Kowalik, A. and Schulze-Bonhage, A. Ad hoc
change from carbamazepine to oxcarbazepine—effectiveness
and tolerance. Nervenarzt 2001; 72: 918–923.
16. Anonymous. Commission on Classification and Terminology
of the International League Against Epilepsy: proposal for re-
vised clinical and encephalographic classification of epileptic
seizures. Epilepsia 1981; 22: 489–501.
17. Anonymous. Commission on Classification and Terminology
of the International League Against Epilepsy: proposal for re-
vised clinical and encephalographic classification of epileptic
seizures. Epilepsia 1989; 30: 389–399.
18. Shorvon, S. Oxcarbazepine: a review. Seizure 2000; 9: 75–79.
19. Schmidt, D. and Sachdeo, R. Oxcarbazepine for treatment of
partial epilepsy: a review and recommendations for clinical
use. Epilepsy Behavior 2000; 1: 396–405.
20. Bill, P. A., Vigonius, U., Pohlmann, H., Guerreiro, C. A.,
Kochen, S., Saffer, D. et al. A double-blind controlled clin-
ical trial of oxcarbazepine versus phenytoin in adults with
previously untreated epilepsy. Epilepsy Res 1997; 27: 195–
204.
21. Guerreiro, M. M., Vigonius, U., Pohlmann, H., de Manreza,
M. L., Fejerman, N., Antoniuk, S. A. et al. A double-blind
controlled clinical trial of oxcarbazepine versus phenytoin in
children and adolescents with epilepsy. Epilepsy Res 1997;
27: 205–213.
22. Christe, W., Kramer, G., Vigonius, U., Pohlmann, H., Stein-
hoff, B. J., Brodie, M. J. et al. A double-blind controlled
clinical trial: oxcarbazepine versus sodium valproate in adults
with newly diagnosed epilepsy. Epilepsy Res 1997; 26: 451–
460.
23. Gates, J. R., Barkley, G., Tatum, W., D’Souza, J. and Constan-
tine, S. Correlation of efficacy and quality of life in patients
with epilepsy transitioned to oxcarbazepine monotherapy: re-
sults of an open-label study. Neurology 2002; 58 (Suppl 2)
[abstract].
